Target intelligence / Profile preview

Influenza Haemagglutinin Protein (HA)

Target: HA
Molecular classification: Viral surface glycoprotein, Class I fusion protein

Overview

Influenza haemagglutinin (HA) is a homotrimeric glycoprotein on the surface of influenza viruses. It mediates viral attachment to host cells and membrane fusion required for viral entry. HA is a major antigenic protein and a key target for neutralizing antibodies.

Other names: HemagglutininHA proteinInfluenza HA

Mechanism of action

Neutralization of HA by antibodies blocks receptor binding and/or inhibits conformational changes necessary for membrane fusion.

Biological functions

Receptor bindingMembrane fusionViral entryHemagglutination

Disease associations

Infection

Safety considerations

Antigenic drift and shift lead to immune evasion.High variability poses challenges for vaccine development.

Beyond the preview

Go deeper on Influenza Haemagglutinin Protein (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza Haemagglutinin Protein (HA).

Explore the full profile